Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma.
about
Liver resection and transplantation in hepatocellular carcinomaRecent advances in multidisciplinary management of hepatocellular carcinomaSupportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver functionImpact of sustained viral response postcurative therapy of hepatitis C-related hepatocellular carcinoma: a systematic review and meta-analysis.The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma.Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: A meta-analysis with comparison of different types of hepatitisTargeting the inflammation in HCV-associated hepatocellular carcinoma: a role in the prevention and treatmentLong-term effects of antiviral therapy in patients with chronic hepatitis C.Efficacy of mesenchymal stem cells in suppression of hepatocarcinorigenesis in rats: possible role of Wnt signaling.p53-paralog DNp73 oncogene is repressed by IFNα/STAT2 through the recruitment of the Ezh2 polycomb group transcriptional repressor.Optimal duration of treatment for HCV genotype 1 infection in slow responders: a meta-analysis.Hong Kong consensus recommendations on the management of hepatocellular carcinoma.The prevention of infection-associated cancersManagement of hepatocellular carcinoma: an overview of major findings from meta-analysesAlpha-fetoprotein and des-gamma-carboxy-prothrombin at twenty-four weeks after interferon-based therapy predict hepatocellular carcinoma development.Hyperglycemia is a significant prognostic factor of hepatocellular carcinoma after curative therapy.Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study.Severe Hepatitis Promotes Hepatocellular Carcinoma Recurrence via NF-κB Pathway-Mediated Epithelial-Mesenchymal Transition after Resection.A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma.Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence.Adjuvant therapy after curative treatment for hepatocellular carcinoma.HCC: current surgical treatment concepts.Medical therapies for hepatocellular carcinoma: a critical view of the evidence.Acyclic retinoid in chemoprevention of hepatocellular carcinoma: Targeting phosphorylated retinoid X receptor-α for prevention of liver carcinogenesis.Prevention of recurrence after curative treatment for hepatocellular carcinoma.Antiviral therapy after curative treatment of hepatitis B/C virus-related hepatocellular carcinoma: A systematic review of randomized trials.A systematic review and meta-analysis of adjuvant interferon therapy after curative treatment for patients with viral hepatitis-related hepatocellular carcinoma.Pharmaceutical and nutraceutical approaches for preventing liver carcinogenesis: chemoprevention of hepatocellular carcinoma using acyclic retinoid and branched-chain amino acids.Postoperative therapy options for hepatocellular carcinoma.Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based antiviral therapy.Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon.Prediction and prevention of intrahepatic recurrence of hepatocellular carcinoma.Lyso-thermosensitive liposomal doxorubicin: an adjuvant to increase the cure rate of radiofrequency ablation in liver cancer.Hepatitis C viral load predicts tumor recurrence after curative resection of hepatocellular carcinoma regardless of the genotype of hepatitis C virus.The safety and efficacy of peginterferon plus ribavirin in hepatitis C patients concomitant with malignancy other than hepatocellular carcinoma: a multicenter study.Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma--A retrospective multicenter study.Effects of antiviral therapy for hepatitis C following treatment of hepatocellular carcinoma: survey findings of the Japanese Red Cross Liver Study Group.Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor.Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma.Surrogate endpoint for overall survival in assessment of adjuvant therapies after curative treatment for hepatocellular carcinoma: a re-analysis of meta-analyses of individual patients' data.
P2860
Q26823395-7680F8C5-4029-4CFD-B838-D9A460E074B0Q26863748-045C4210-8622-45F6-BDB3-02F056872E73Q28066295-DB04A46B-B253-4615-B208-BDB8582D277FQ30241048-06B5E2B0-560D-413C-B24A-91EB9D93DE30Q30250096-C23326D7-0B1A-4093-BF95-7EEB23000A79Q34265805-864D111E-FCA9-440F-9D63-78E73A106D49Q34347862-6C57B4E5-A1EA-4486-AC4B-6F5950637694Q34415157-8D4D7DEA-4425-4481-9ECF-049695BC3885Q35041516-F76D6F32-5A44-406C-B433-7FC23F81D17FQ35042810-0E601193-6CE8-4909-80F0-FF55E671EF26Q35582452-1249F36B-EF7C-4113-A645-A39A7A1236B8Q35631295-1DBC7CAF-B78D-4C80-B474-D084DCF91348Q35857515-D7E06317-554B-433A-8435-1F09D2E3AE5AQ36014255-8BC483C3-69DB-4BAD-B156-AD0EAD7DF69FQ36329125-DFBEFF17-D6AC-40E7-91A8-853D01A6CF38Q36541200-68C3A270-DE73-47FC-B864-77729E3D44F5Q36745162-2D8A7AE1-C14C-470B-9815-F0E641E2E3FDQ36759142-836C3A63-495B-4AB6-A243-76144F4CB331Q36934253-C8205416-6543-4BAB-A9C1-ADC79E0BB62CQ37701106-C82B93E6-93A3-40CF-9973-4E5D4AF776DFQ37972807-D53BFC34-E19D-4F01-BCEF-3595BABB3373Q37980015-29916217-4174-45EE-9A48-DF7DEEF021E9Q38059437-90A45B0C-4BBC-46F2-84D2-59266B925DFEQ38066478-13CD5550-7ED9-433E-919E-444303C4D733Q38070128-46A3E107-394B-4CCA-89DC-DBF493B0EBD6Q38100807-0D14C2EF-4688-4E6C-936E-EBCE7257044CQ38134777-2F294B42-0553-468E-B74A-54DCBAABB7ABQ38165918-36D60F7E-08DC-4012-8BFE-667BDB59BE39Q38203306-4C5223EF-4593-4808-B7C1-ED7B02943588Q38232812-BF7F3B61-F52D-429C-9640-4DA4C0B8F050Q39240225-269F324D-34DB-4111-90AB-DA25C065EBEBQ39674275-15479016-E3C8-44D8-BE6A-2A97DDD955D1Q39720049-D9DB5F40-3BF5-41AD-8212-FD456B598326Q40706056-E09DDD16-EE70-41A3-BA79-37C116600093Q40707621-6119FA45-424E-48EC-83CF-ECF188357792Q41430815-D72C647F-9121-499D-BDB3-9C84CBE2B413Q42156187-B31DBCEC-0899-41B4-8623-6EFAE910E384Q42164795-37D40F20-B62E-47A9-89A3-2CFCB483A408Q45352726-2E4A09D9-80BA-4C37-856F-A1104996EA53Q47098597-6808957B-D365-4D7A-8B2A-E71FAE685701
P2860
Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma.
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Meta-analysis: interferon-alph ...... ated hepatocellular carcinoma.
@ast
Meta-analysis: interferon-alph ...... ated hepatocellular carcinoma.
@en
Meta-analysis: interferon-alph ...... ated hepatocellular carcinoma.
@nl
type
label
Meta-analysis: interferon-alph ...... ated hepatocellular carcinoma.
@ast
Meta-analysis: interferon-alph ...... ated hepatocellular carcinoma.
@en
Meta-analysis: interferon-alph ...... ated hepatocellular carcinoma.
@nl
prefLabel
Meta-analysis: interferon-alph ...... ated hepatocellular carcinoma.
@ast
Meta-analysis: interferon-alph ...... ated hepatocellular carcinoma.
@en
Meta-analysis: interferon-alph ...... ated hepatocellular carcinoma.
@nl
P2093
P2860
P1476
Meta-analysis: interferon-alph ...... ated hepatocellular carcinoma.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2893.2009.01181.X
P577
2009-09-02T00:00:00Z